COSMO Pharmaceuticals SA (0RGI) - Net Assets

Latest as of June 2025: £466.98 Million GBP ≈ $627.11 Million USD

Based on the latest financial reports, COSMO Pharmaceuticals SA (0RGI) has net assets worth £466.98 Million GBP (≈ $627.11 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (£610.33 Million ≈ $819.62 Million USD) and total liabilities (£143.35 Million ≈ $192.51 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 0RGI cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	£466.98 Million
% of Total Assets	76.51%
Annual Growth Rate	N/A
5-Year Change	26.23%
10-Year Change	25.13%
Growth Volatility	200.29

COSMO Pharmaceuticals SA - Net Assets Trend (2004–2024)

This chart illustrates how COSMO Pharmaceuticals SA's net assets have evolved over time, based on quarterly financial data. Also explore COSMO Pharmaceuticals SA total assets for the complete picture of this company's asset base.

Annual Net Assets for COSMO Pharmaceuticals SA (2004–2024)

The table below shows the annual net assets of COSMO Pharmaceuticals SA from 2004 to 2024. For live valuation and market cap data, see COSMO Pharmaceuticals SA stock valuation.

Year	Net Assets	Change
2024-12-31	£505.09 Million ≈ $678.29 Million	+17.73%
2023-12-31	£429.04 Million ≈ $576.16 Million	-7.49%
2022-12-31	£463.79 Million ≈ $622.83 Million	-9.54%
2021-12-31	£512.68 Million ≈ $688.48 Million	+28.13%
2020-12-31	£400.12 Million ≈ $537.33 Million	+1.62%
2019-12-31	£393.73 Million ≈ $528.75 Million	-11.49%
2018-12-31	£444.85 Million ≈ $597.40 Million	-5.37%
2017-12-31	£470.12 Million ≈ $631.32 Million	+13.13%
2016-12-31	£415.56 Million ≈ $558.06 Million	+2.95%
2015-12-31	£403.65 Million ≈ $542.06 Million	+165.05%
2014-12-31	£152.29 Million ≈ $204.51 Million	-30.83%
2013-12-31	£220.16 Million ≈ $295.65 Million	+76.69%
2012-12-31	£124.60 Million ≈ $167.33 Million	+96.43%
2011-12-31	£63.43 Million ≈ $85.19 Million	+8.68%
2010-12-31	£58.37 Million ≈ $78.38 Million	-2.39%
2009-12-31	£59.80 Million ≈ $80.30 Million	+38.30%
2008-12-31	£43.24 Million ≈ $58.06 Million	+23.01%
2007-12-31	£35.15 Million ≈ $47.20 Million	+557.69%
2006-12-31	£5.34 Million ≈ $7.18 Million	+746.91%
2005-12-31	£631.00K ≈ $847.38K	+171.70%
2004-12-31	£-880.00K ≈ $-1.18 Million	--

Equity Component Analysis

This analysis shows how different components contribute to COSMO Pharmaceuticals SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 32696900000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	£323.06 Million	64.83%
Common Stock	£4.56 Million	0.92%
Other Comprehensive Income	£-19.28 Million	-3.87%
Other Components	£189.99 Million	38.12%
Total Equity	£498.33 Million	100.00%

COSMO Pharmaceuticals SA Competitors by Market Cap

The table below lists competitors of COSMO Pharmaceuticals SA ranked by their market capitalization.

Company	Market Cap
Perrigo Company PLC NYSE:PRGO	$1.64 Billion
J & J Snack Foods Corp NASDAQ:JJSF	$1.64 Billion
Mayinglong Pharmaceutical Group Co Ltd SHG:600993	$1.64 Billion
Peloton Interactive Inc NASDAQ:PTON	$1.64 Billion
Shanxi Huaxiang Group Co Ltd SHG:603112	$1.64 Billion
Sinostone Guangdong Co Ltd SHE:001212	$1.64 Billion
Shenzhen Urban Transport Planning Center Co. Ltd. SHE:301091	$1.64 Billion
IGNITIS GRUPE AB EO 2233 F:IGV0	$1.64 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in COSMO Pharmaceuticals SA's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 422,160,000 to 498,330,000, a change of 76,170,000 (18.0%).
Net income of 133,236,000 contributed positively to equity growth.
Dividend payments of 32,094,000 reduced retained earnings.
Share repurchases of 5,931,000 reduced equity.
Other comprehensive income increased equity by 1,897,000.
Other factors decreased equity by 20,938,000.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	£133.24 Million	+26.74%
Dividends Paid	£32.09 Million	-6.44%
Share Repurchases	£5.93 Million	-1.19%
Other Comprehensive Income	£1.90 Million	+0.38%
Other Changes	£-20.94 Million	-4.2%
Total Change	£-	18.04%

Book Value vs Market Value Analysis

This analysis compares COSMO Pharmaceuticals SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.68x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2004-12-31	£-0.38	£81.43	x
2005-12-31	£0.25	£81.43	x
2006-12-31	£0.61	£81.43	x
2007-12-31	£2.63	£81.43	x
2008-12-31	£3.12	£81.43	x
2009-12-31	£4.03	£81.43	x
2010-12-31	£3.92	£81.43	x
2011-12-31	£4.38	£81.43	x
2012-12-31	£9.03	£81.43	x
2013-12-31	£15.39	£81.43	x
2014-12-31	£10.44	£81.43	x
2015-12-31	£28.03	£81.43	x
2016-12-31	£28.85	£81.43	x
2017-12-31	£31.74	£81.43	x
2018-12-31	£29.57	£81.43	x
2019-12-31	£26.91	£81.43	x
2020-12-31	£27.65	£81.43	x
2021-12-31	£29.89	£81.43	x
2022-12-31	£27.82	£81.43	x
2023-12-31	£26.21	£81.43	x
2024-12-31	£30.35	£81.43	x

Capital Efficiency Dashboard

This dashboard shows how efficiently COSMO Pharmaceuticals SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 26.74%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 49.94%
• Asset Turnover: 0.41x
• Equity Multiplier: 1.30x
Recent ROE (26.74%) is above the historical average (16.80%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2004	0.00%	-19.92%	0.47x	0.00x	£-2.11 Million
2005	132.81%	5.40%	0.55x	44.71x	£774.90K
2006	-2.56%	-0.90%	0.64x	4.42x	£-671.40K
2007	0.33%	0.53%	0.46x	1.34x	£-3.40 Million
2008	21.74%	27.51%	0.59x	1.34x	£5.08 Million
2009	6.77%	15.18%	0.37x	1.20x	£-1.93 Million
2010	6.21%	11.25%	0.35x	1.58x	£-2.20 Million
2011	12.04%	22.70%	0.43x	1.23x	£1.29 Million
2012	15.53%	32.46%	0.39x	1.22x	£6.88 Million
2013	31.22%	121.94%	0.23x	1.10x	£46.72 Million
2014	48.15%	92.12%	0.35x	1.48x	£58.09 Million
2015	61.49%	409.51%	0.14x	1.08x	£207.83 Million
2016	4.65%	28.58%	0.15x	1.07x	£-22.21 Million
2017	-6.90%	-48.25%	0.14x	1.06x	£-79.46 Million
2018	-4.07%	-27.52%	0.10x	1.41x	£-62.43 Million
2019	-6.22%	-39.19%	0.11x	1.49x	£-63.87 Million
2020	-1.97%	-12.96%	0.10x	1.49x	£-47.91 Million
2021	4.29%	33.30%	0.08x	1.59x	£-28.86 Million
2022	3.77%	16.87%	0.13x	1.66x	£-28.47 Million
2023	-1.17%	-5.32%	0.17x	1.31x	£-47.15 Million
2024	26.74%	49.94%	0.41x	1.30x	£83.40 Million

Industry Comparison

This section compares COSMO Pharmaceuticals SA's net assets metrics with peer companies in the same industry.

Industry Context

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
COSMO Pharmaceuticals SA (0RGI)	£466.98 Million	0.00%	0.31x	$1.64 Billion
Kambi Group PLC Series B (0EAW)	$20.06 Million	0.00%	0.45x	$494.35 Million
Embracer Group AB Series B (0GFE)	$52.48 Billion	-34.63%	0.82x	$598.03 Million
STMicroelectronics NV (0INB)	$8.25 Billion	8.41%	0.86x	$489.99K
Uniti Group Inc. (0LJB)	$-1.48 Billion	0.00%	0.00x	$2.17 Billion
RTL Group SA (0MNC)	$3.29 Billion	22.90%	1.73x	$341.55K
Subsea 7 SA (0OGK)	$5.68 Billion	3.21%	0.33x	$331.83K
Stolt-Nielsen Limited (0OHK)	$1.43 Billion	5.39%	1.74x	$1.93 Billion
Aperam SA (0OLF)	$2.52 Billion	11.37%	0.72x	$523.99K
Gedeon Richter PLC (0QFP)	$678.00 Billion	9.76%	0.20x	$64.85 Million
Creades AB Series A (0QI9)	$11.15 Billion	10.87%	0.01x	$94.84 Million

About COSMO Pharmaceuticals SA

LSE:0RGI UK

Market Cap

$1.64 Billion

£1.22 Billion GBP

Market Cap Rank

#7004 Global

#17 in UK

Share Price

£81.43

Change (1 day)

-3.22%

52-Week Range

£47.95 - £125.25

All Time High

£173.85